Trial NCT02657369

View at ClinicalTrials.gov 
Org. Study IDs: E7080-M000-213
Secondary IDs: 2015-001929-17

Last trial update was posted on 2019-10-15

MeSH Interventions

Lenvatinib

MeSH Conditions

Carcinoma Thyroid Carcinoma, Anaplastic Thyroid Diseases Thyroid Neoplasms

Other Conditions


Stopping Reasons

Overall response rate was 3% (only 1 out of 33 participants had confirmed PR).

Limitations And Caveats

The study was terminated since overall response rate was 3% (only 1 out of 33 participants had confirmed PR).

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID